3 products found
GENFIT Products
-
Elafibranor in PBC
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory activity. The use of drugs targeting PPAR receptors has been shown to reduce blood ...
-
Novel Technology to Power a Blood-Based Test for NASH
Nonalcoholic steatohepatitis (NASH) remains largely underdiagnosed, as it carries no obvious symptoms in its early stages, and also because of the lack of widely available non-invasive tests specifically developed to diagnose the disease. The underdiagnosis of NASH represents a major unmet need, and is a barrier for identification of patients at higher risk for disease progression, who would be eligible for therapeutic ...
-
Nitazoxanide in NASH-Induced Fibrosis
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential treatment of NASH-induced significant liver fibrosis. For more ...